Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Rating Lowered by Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

NASDAQ BDRX opened at $0.83 on Friday. The company’s 50 day moving average is $1.57 and its 200-day moving average is $4.23. Biodexa Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $26.50.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up about 0.6% of Sabby Management LLC’s holdings, making the stock its 10th biggest position. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.